Patricia Bernardo

1.6k total citations · 1 hit paper
20 papers, 1.0k citations indexed

About

Patricia Bernardo is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, Patricia Bernardo has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Molecular Biology and 7 papers in Epidemiology. Recurrent topics in Patricia Bernardo's work include Clostridium difficile and Clostridium perfringens research (6 papers), Gut microbiota and health (6 papers) and HER2/EGFR in Cancer Research (4 papers). Patricia Bernardo is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (6 papers), Gut microbiota and health (6 papers) and HER2/EGFR in Cancer Research (4 papers). Patricia Bernardo collaborates with scholars based in United States, United Kingdom and Canada. Patricia Bernardo's co-authors include James N. Ingle, William C. Wood, George W. Sledge, Silvana Martino, Donna Neuberg, Eric K. Rowinsky, Nancy E. Davidson, William J. Gradishar, Stanley Zucker and Joseph A. Sparano and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer.

In The Last Decade

Patricia Bernardo

20 papers receiving 1000 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

2003 524 citations George W. Sledge, Donna Neuberg et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Patricia Bernardo

Since Specialization

Citations

This map shows the geographic impact of Patricia Bernardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Bernardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Bernardo more than expected).

Fields of papers citing papers by Patricia Bernardo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Bernardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Bernardo. The network helps show where Patricia Bernardo may publish in the future.

Co-authorship network of co-authors of Patricia Bernardo

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Bernardo. A scholar is included among the top collaborators of Patricia Bernardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Bernardo. Patricia Bernardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076) 2022 ·Gynecologic Oncology ·Debra L. Richardson, Erika Hamilton, Minal Barve, Charles Anderson, Sara Taylor, Nehal J. Lakhani, Joseph Buscema, Anthony W. Tolcher, Corrine Zarwan, Theresa L. Werner, John L. Hays, Rebecca C. Arend, (unknown), Emily Putiri, Patricia Bernardo, Robert A. Burger, Ursula A. Matulonis	12
2	Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588) 2022 ·Gynecologic Oncology ·Nehal J. Lakhani, Timothy F. Burns, Minal Barve, (unknown), John L. Hays, Corrine Zarwan, Theresa L. Werner, Charles Anderson, Joseph Buscema, Patricia Bernardo, Erika Krasnickas Keeton, (unknown), Robert A. Burger	1
3	Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer. 2021 ·Journal of Clinical Oncology ·Debra L. Richardson, Erika Hamilton, Ana Oaknin, Leslie M. Randall, Susana Banerjee, Sara Taylor, Linda Mileshkin, Robert L. Coleman, Bradley J. Monk, Mansoor Raza Mirza, Patricia Bernardo, Rebecca Mosher, Valerie M. Jansen, Antonella Savarese, Toon Van Gorp, Radosław Mądry, Isabelle Laure Ray-Coquard, Nicole Concin	9
4	184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer 2021 ·INFM-OAR (INFN Catania) ·Nicole Concin, Erika Hamilton, (unknown), Susana Banerjee, Linda Mileshkin, R. Coleman, Bradley J. Monk, (unknown), Antonella Savarese, Isabelle Ray‐Coquard, (unknown), Patricia Bernardo, Emily Putiri, Robert A. Burger, Rebecca Mosher, D. Richardson, David Cibula, Radosław Mądry, Radoslav Chekerov, Toon Van Gorp	4
5	1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI) 2019 ·Open Forum Infectious Diseases ·Christopher B. Ford, (unknown), Barbara McGovern, Darrell S. Pardi, Richard Nathan, (unknown), Robert T. Brennan, John Pullman, Patricia Bernardo, Amelia D. Tomlinson, Kevin Horgan, Jessica A. Bryant, (unknown), (unknown), (unknown), Elaine Wang, (unknown)	9
6	Tu2019 - Engraftment of Ser-287, an Investigational Microbiome Therapeutic, is Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in Patients with Active Mild to Moderate Ulcerative Colitis (UC) 2018 ·Gastroenterology ·Sheri L. Simmons, (unknown), Edward R. O’Brien, Meghan Chafee, (unknown), Patricia Bernardo, David N. Cook, Michele Trucksis, Matthew R. Henn	3
7	621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner 2018 ·Open Forum Infectious Diseases ·Matthew R. Henn, Christopher B. Ford, Edward R. O’Brien, Jennifer R. Wortman, (unknown), Christopher A. Desjardins, Amelia D. Tomlinson, (unknown), Mark H. Wilcox, Anthony M. Buckley, Patricia Bernardo, Barbara McGovern, John Auniņš, David N. Cook, Michele Trucksis	1
8	85 - SER-287, an Investigational Microbiome Therapeutic, Induces Remission and Endoscopic Improvement in a Placebo-Controlled, Double-Blind Randomized Trial in Patients with Active Mild-to-Moderate Ulcerative Colitis 2018 ·Gastroenterology ·(unknown), John Curran, Hans Herfarth, Kiran Jagarlamudi, (unknown), Bal Raj Bhandari, Gregory Wiener, David H. Kerman, Alan C. Moss, Roger J. Pomerantz, (unknown), Patricia Bernardo, Sheri L. Simmons, (unknown), Edward R. O’Brien, Matthew R. Henn, Michele Trucksis	4
9	1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes 2018 ·Open Forum Infectious Diseases ·Christopher B. Ford, Matthew R. Henn, Jessica A. Bryant, (unknown), Jennifer R. Wortman, Amelia D. Tomlinson, (unknown), Patricia Bernardo, Barbara McGovern, John Auniņš, David N. Cook, Michele Trucksis	1
10	P421 SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with active mild-to-moderate ulcerative colitis 2018 ·Journal of Crohn s and Colitis ·(unknown), John Curran, Hans Herfarth, (unknown), Caterina Oneto, Bal Raj Bhandari, Gregory Wiener, David H. Kerman, Alan C. Moss, Roger J. Pomerantz, (unknown), Patricia Bernardo, Sheri L. Simmons, (unknown), Edward R. O’Brien, Matthew R. Henn, Michele Trucksis	5
11	Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI) 2017 ·Open Forum Infectious Diseases ·Matthew R. Henn, Christopher B. Ford, Edward R. O’Brien, Jennifer R. Wortman, Sheri L. Simmons, (unknown), (unknown), Patricia Bernardo, John Auniņš, David N. Cook, Michele Trucksis	3
12	Clinical Outcomes of Ceftolozane/Tazobactam Treatment of Piperacillin/Tazobactam and Ceftazidime Non-Susceptible Pathogens From Two Phase 3 Trials and Associated in Vitro Activity 2015 ·Open Forum Infectious Diseases ·Myra W. Popejoy, Eliana S. Armstrong, Benjamin Miller, (unknown), Patricia Bernardo, Judith N. Steenbergen, David J. Farrell, Ellie Hershberger	1
13	The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas 2009 ·International Journal of Clinical Practice ·Peter Pertel, Barry I. Eisenstein, Arthur S. Link, (unknown), (unknown), Patricia Bernardo, W. J. Martone	45
14	A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596): A Trial of the Eastern Cooperative Oncology Group 2009 ·Journal of Thoracic Oncology ·Leora Horn, Patricia Bernardo, Alan Sandler, Henry Wagner, Nathan Levitan, Mark L. Levitt, David H. Johnson	13
15	Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia 2008 ·Clinical Infectious Diseases ·Peter Pertel, Patricia Bernardo, Charles Fogarty, (unknown), R Northland, Mark Benvenuto, Grace M. Thorne, Steven A. Luperchio, Robert D. Arbeit, Jeff Alder	106
16	Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group 2007 ·Journal of Immunotherapy ·Hossein Borghaei, R. Katherine Alpaugh, Patricia Bernardo, (unknown), Janice P. Dutcher, (unknown), William C. Wood, Lori J. Goldstein, Louis M. Weiner	20
17	Changes in the natural history of nonsmall cell lung cancer (NSCLC)—Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990 2006 ·Cancer ·Heather A. Wakelee, Patricia Bernardo, David H. Johnson, Joan H. Schiller	51
18	Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196 2004 ·Journal of Clinical Oncology ·Joseph A. Sparano, Patricia Bernardo, Patricia Stephenson, William J. Gradishar, James N. Ingle, Stanley Zucker, Nancy E. Davidson	196
19	Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) breakdown → 2003 ·Journal of Clinical Oncology ·George W. Sledge, Donna Neuberg, Patricia Bernardo, James N. Ingle, Silvana Martino, Eric K. Rowinsky, William C. Wood	524
20	Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (Tx): Implications of ECOG 5592 2000 ·Lung Cancer ·Corey J. Langer, Judith Manola, Patricia Bernardo, Philip Bonomi, (unknown), David H. Johnson	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact